ReviewBMC nephrology2025
Renal hypouricemia type 2 in a patient with latent autoimmune diabetes in adults: a case report and literature review.
Review in BMC nephrology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLatent autoimmune diabetes in adults (LADA) is recognized as the most prevalent form of autoimmune diabetes in adulthood marked by a long-term preservation of endogenous insulin secretion capacity. Renal hypouricemia type 2 (RHUC2) is a rare genetic disorder characterized by defective uric acid reabsorption which results from variants in the SLC2A9 gene. Currently, there are no reported cases of RHUC2 combined with LADA. CASE PRESENTATION: A 39-year-old servicewoman visited our hospital with the complaint of elevated blood glucose for 2 years and polydipsia, polyuria, numb right thumb for 4 months. Laboratory tests showed a high value of glucose in both urine and blood, total cholesterol (TC), triglyceride (TG), low density lipoprotein cholesterol (LDL-C), glycosylated hemoglobin (HbA1c) and anti-glutamic acid decarboxylase antibody (GADA), and a low value of fasting immunoreactive insulin (IRI) and C-peptide (C-P). She had a history of hypothyroidism for 6 years. Therefore, the patient was initially diagnosed with LADA, primary hypothyroidism and hyperlipidemia. Later, laboratory tests revealed an extremely low level of uric acid and a high value of fractional excretion of uric acid (FEUA). Two SLC2A9 heterozygous mutations, one PPP1R3A heterozygous mutation and one FOXD3 variation were found through gene analysis. Finally, the patient was diagnosed with RHUC2, LADA, Hashimoto’s thyroiditis, hyperlipidemia and antiphospholipid syndrome (APS).
conclusionTwo SLC2A9 heterozygous mutations, c. 227C > A and c. 1343C > T, were identified in the patient. These characteristics indicated that the patient was suffered from RHUC2.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.